Danaher Corporation (DHR)

NYSE
Currency in USD
184.54
-2.94(-1.57%)
Closed·
After Hours
184.79+0.25(+0.14%)
·
DHR Scorecard
Full Analysis
Management has been aggressively buying back shares
DHR is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
183.05185.99
52 wk Range
171.00281.70
Key Statistics
Edit
Prev. Close
187.48
Open
184.36
Day's Range
183.05-185.99
52 wk Range
171-281.7
Volume
2.81M
Average Vol. (3m)
4.29M
1-Year Change
-29.77%
Book Value / Share
71.07
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DHR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
247.05
Upside
+33.87%
Members' Sentiments
Bearish
Bullish
ProTips
High shareholder yield
Show more

Danaher Corporation Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment offers bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. Its Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services in the areas of clinical chemistry, immunoassay, hematology, and microbiology for hospitals, physicians’ offices, reference laboratories, and other critical care settings. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District Of Columbia.

Danaher Corporation SWOT Analysis


Market Dynamics
Average analyst price target of $284, reflecting varied perspectives on Danaher's growth potential amid biotech recovery and ongoing challenges in China
Strategic Evolution
Explore Danaher's proactive cost-saving measures and operational efficiencies, aimed at expanding margins into the mid-30s and enhancing shareholder value
Financial Trajectory
Analysts project steady growth for Danaher, with revenue expected to reach $27.67B by 2027 and EPS rising to $9.56, showcasing strong financial outlook
Life Sciences Leade
Danaher Corporation, a $150B market cap giant, dominates life sciences, diagnostics, and CROs sectors with robust financial health and strategic market positioning
Read full SWOT analysis

Danaher Corporation Earnings Call Summary for Q1/2025

  • Danaher beats Q1 2025 estimates: EPS $1.88 vs $1.62 forecast, revenue $5.74B vs $5.56B expected; stock jumps 5.1% in premarket
  • Core revenue flat YoY; company targets $150M cost savings via restructuring; China market sees high single-digit decline
  • Full-year 2025 guidance: ~3% core revenue growth, adjusted EPS $7.60-$7.75; Q2 expects low single-digit core revenue growth
  • Strong financial health: 61.2% gross margin, $1.1B free cash flow; 33-year dividend track record, 7 years of consecutive growth
  • CEO emphasizes market strength; CFO notes strategic flexibility amid evolving landscape and potential market opportunities
Last Updated: 04/22/2025, 09:24 AM
Read Full Transcript

Compare DHR to Peers and Sector

Metrics to compare
DHR
Peers
Sector
Relationship
P/E Ratio
35.1x−1.5x−0.4x
PEG Ratio
−2.790.080.00
Price / Book
2.6x1.4x2.6x
Price / LTM Sales
5.5x4.5x2.9x
Upside (Analyst Target)
31.4%34.5%54.4%
Fair Value Upside
Unlock31.3%9.3%Unlock

Analyst Ratings

24 Buy
3 Hold
0 Sell
Ratings:
27 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 247.05
(+33.87% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 5.19%
Dividend Yield
0.69%
Industry Median 0.75%
Annualized Payout
1.28
Paid quarterly
5-Years Growth
+10.37%
Growth Streak

Earnings

Latest Release
Apr 22, 2025
EPS / Forecast
1.88 / 1.62
Revenue / Forecast
5.74B / 5.56B
EPS Revisions
Last 90 days

People Also Watch

480.43
DPZ
-0.38%
184.42
STZ
-0.18%
100.46
VLTO
-0.51%
206.82
TEAM
-0.74%

FAQ

What Is the Danaher (DHR) Stock Price Today?

The Danaher stock price today is 184.54

What Stock Exchange Does Danaher Trade On?

Danaher is listed and trades on the New York Stock Exchange stock exchange.

What Is the Stock Symbol for Danaher?

The stock symbol for Danaher is "DHR."

Does Danaher Pay Dividends? What’s The Current Dividend Yield?

The Danaher dividend yield is 0.69%.

What Is the Danaher Market Cap?

As of today, Danaher market cap is 132.07B.

What Is Danaher's Earnings Per Share (TTM)?

The Danaher EPS (TTM) is 5.19.

When Is the Next Danaher Earnings Date?

Danaher will release its next earnings report on Jul 29, 2025.

From a Technical Analysis Perspective, Is DHR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Danaher Stock Split?

Danaher has split 5 times.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.